Astellas Pharma Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Astellas Pharma stock.
View analyst ratings for Astellas Pharma or view top-rated stocks.

Wall Street analysts have given Astellas Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Astellas Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Astellas Pharma saw a decline in short interest during the month of January. As of January 29th, there was short interest totaling 11,500 shares, a decline of 85.3% from the January 14th total of 78,400 shares. Based on an average trading volume of 186,100 shares, the days-to-cover ratio is currently 0.1 days.
View Astellas Pharma's Short Interest.

Astellas Pharma is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Astellas Pharma.

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Friday, January, 29th. The company reported $0.31 EPS for the quarter. The business had revenue of $3.12 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 13.24% and a net margin of 11.03%.
View Astellas Pharma's earnings history.

Astellas Pharma's stock was trading at $15.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALPMY shares have increased by 1.0% and is now trading at $15.87.
View which stocks have been most impacted by COVID-19.

Astellas Pharma pays an annual dividend of $0.29 per share and currently has a dividend yield of 1.76%. The dividend payout ratio of Astellas Pharma is 30.21%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 19.08% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.
View Astellas Pharma's dividend history.

Astellas Pharma's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Some companies that are related to Astellas Pharma include Sanofi (SNY), CSL (CSLLY), GlaxoSmithKline (GSK), Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BeiGene (BGNE), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF) and MERCK Kommanditgesellschaft auf Aktien (MKGAF).
View all of ALPMY's competitors.

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPMY stock can currently be purchased for approximately $15.87.

Astellas Pharma has a market capitalization of $29.55 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis.

Astellas Pharma employs 15,883 workers across the globe.

The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.

Astellas Pharma was founded in 1923.

The official website for Astellas Pharma is www.astellas.com.

Astellas Pharma is headquartered at 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411.

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.